450 enrollment should be enough, right?....1/3 in each enrollment (150) noticed on 8K that 2month data so far stock dropping from overbought condition need to watch this more for today may or may not reflect the DSMB reasons appreciate your comments
With non-adaptive studies, the vast majority of time, DSMB reviews are followed by a recommendation to continue the study as planned. It would be surprising to stop a study in a neurodegenerative disease for either profound success or complete failure (treated would have to be worse than placebo). So there is no surprise. The SP reaction today may be due to a realization that the company has insufficient cash to complete the study as planned (not a reduced n) and still have enough cash to fund continuing operations and fund a reserve. They need a larger cushion of cash in this environment of higher rates and cautious investors. It would be unwise to allow cash to get too low and I suspect they will need to raise funds by the end of the year. Coupled with what is certain, now, to be a nonevent presentation, the price is going to be range bound. In retropspect, its easy to say that they should have raised more cash May-July 2021. I hold no current position, just an observation.